髓系来源的抑制性细胞在癌症中的可塑性。
Plasticity of myeloid-derived suppressor cells in cancer.
机构信息
The Wistar Institute, Philadelphia, PA 19104, United States.
University of Pennsylvania, Philadelphia, PA, United States.
出版信息
Curr Opin Immunol. 2018 Apr;51:76-82. doi: 10.1016/j.coi.2018.03.009. Epub 2018 Mar 14.
Abstract
In recent years, myeloid-derived suppressor cells (MDSC) have emerged as one of the major inhibitors of immune effector cell function in cancer. MDSC represent a heterogeneous population of largely immature myeloid cells that are characterized by a pathological state of activation and display potent immune suppressive activity. Two major subsets of MDSC have been identified: monocytic (M-MDSC) and polymorphonuclear (PMN-MDSC). PMN-MSDC share phenotypic and morphologic features with neutrophils, whereas M-MDSC are similar to monocytes and are characterized by high plasticity. Differentiation of M-MDSC to macrophages and dendritic cells is shaped by tumor microenvironment. In recent years, the mechanisms of this process start to emerge.
摘要
近年来，髓系来源的抑制细胞（MDSC）已成为癌症中免疫效应细胞功能的主要抑制物之一。MDSC 是一群异质性的、主要处于未成熟状态的髓系细胞，其特征为病理性激活，并具有强大的免疫抑制活性。已经确定了 MDSC 的两个主要亚群：单核细胞来源的（M-MDSC）和多形核粒细胞来源的（PMN-MDSC）。PMN-MSDC 具有与中性粒细胞相似的表型和形态特征，而 M-MDSC 则类似于单核细胞，具有高可塑性。M-MDSC 向巨噬细胞和树突状细胞的分化受肿瘤微环境的影响。近年来，这一过程的机制开始显现。
相似文献
1
Plasticity of myeloid-derived suppressor cells in cancer.
Curr Opin Immunol. 2018 Apr;51:76-82. doi: 10.1016/j.coi.2018.03.009. Epub 2018 Mar 14.
2
Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.
J Immunol. 2018 Jan 15;200(2):422-431. doi: 10.4049/jimmunol.1701019.
3
Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity.
Front Immunol. 2022 Jan 18;12:803014. doi: 10.3389/fimmu.2021.803014. eCollection 2021.
4
Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells.
Semin Immunol. 2016 Apr;28(2):187-96. doi: 10.1016/j.smim.2016.03.018. Epub 2016 Apr 7.
5
Tumor promoting capacity of polymorphonuclear myeloid-derived suppressor cells and their neutralization.
Int J Cancer. 2021 Nov 1;149(9):1628-1638. doi: 10.1002/ijc.33731. Epub 2021 Jul 17.
6
The Development and Homing of Myeloid-Derived Suppressor Cells: From a Two-Stage Model to a Multistep Narrative.
Front Immunol. 2020 Oct 26;11:557586. doi: 10.3389/fimmu.2020.557586. eCollection 2020.
7
AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells.
Cancer Res. 2019 Oct 1;79(19):5034-5047. doi: 10.1158/0008-5472.CAN-19-0880. Epub 2019 Aug 13.
8
Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cells.
J Cancer Res Ther. 2021 Jul-Sep;17(4):1093-1100. doi: 10.4103/jcrt.JCRT_1222_20.
9
Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs).
Clin Cancer Res. 2016 Aug 1;22(15):3924-36. doi: 10.1158/1078-0432.CCR-15-2463. Epub 2016 Mar 8.
10
Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer.
JCI Insight. 2020 Aug 6;5(15):138581. doi: 10.1172/jci.insight.138581.
引用本文的文献
1
Lnk deficiency attenuates the immunosuppressive capacity of MDSCs via ferroptosis to suppress tumor development.
Cell Death Dis. 2025 Aug 12;16(1):610. doi: 10.1038/s41419-025-07948-8.
2
Plasticity of myeloid-derived suppressor cells in cancer and cancer therapy.
Oncol Res. 2025 Jun 26;33(7):1581-1592. doi: 10.32604/or.2025.060063. eCollection 2025.
3
Modulating the tumor microenvironment: The role of traditional Chinese medicine in improving lung cancer treatment.
Open Life Sci. 2025 May 20;20(1):20251100. doi: 10.1515/biol-2025-1100. eCollection 2025.
4
Dual roles of methylglyoxal in cancer.
Front Oncol. 2025 Apr 25;15:1557162. doi: 10.3389/fonc.2025.1557162. eCollection 2025.
5
Neutrophils in cancer: At the crucial crossroads of anti-tumor and pro-tumor.
Cancer Commun (Lond). 2025 Aug;45(8):888-913. doi: 10.1002/cac2.70027. Epub 2025 Apr 29.
6
Myeloid cells: key players in tumor microenvironments.
Front Med. 2025 Apr;19(2):265-296. doi: 10.1007/s11684-025-1124-8. Epub 2025 Mar 6.
7
The Recruitment and Immune Suppression Mechanisms of Myeloid-Derived Suppressor Cells and Their Impact on Bone Metastatic Cancer.
Cancer Rep (Hoboken). 2025 Feb;8(2):e70044. doi: 10.1002/cnr2.70044.
8
Harnessing amino acid pathways to influence myeloid cell function in tumor immunity.
Mol Med. 2025 Feb 4;31(1):44. doi: 10.1186/s10020-025-01099-4.
9
Immunosenescence, Physical Exercise, and their Implications in Tumor Immunity and Immunotherapy.
Int J Biol Sci. 2025 Jan 6;21(3):910-939. doi: 10.7150/ijbs.100948. eCollection 2025.
10
Bidirectional role of neutrophils in tumor development.
Mol Cancer. 2025 Jan 16;24(1):22. doi: 10.1186/s12943-025-02228-7.
本文引用的文献
1
Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells.
Oncoimmunology. 2017 Jun 30;6(10):e1344804. doi: 10.1080/2162402X.2017.1344804. eCollection 2017.
2
Aryl Hydrocarbon Receptor Controls Monocyte Differentiation into Dendritic Cells versus Macrophages.
Immunity. 2017 Sep 19;47(3):582-596.e6. doi: 10.1016/j.immuni.2017.08.016.
3
Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression.
Immunity. 2017 Aug 15;47(2):323-338.e6. doi: 10.1016/j.immuni.2017.07.014.
4
Inflammatory Ly6Chi monocytes and their conversion to M2 macrophages drive atherosclerosis regression.
J Clin Invest. 2017 Aug 1;127(8):2904-2915. doi: 10.1172/JCI75005. Epub 2017 Jun 26.
5
Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.
Sci Immunol. 2016 Aug;1(2). doi: 10.1126/sciimmunol.aaf8943. Epub 2016 Aug 5.
6
The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2.
Mol Cell. 2017 Feb 16;65(4):730-742.e5. doi: 10.1016/j.molcel.2017.01.021.
7
Dendritic cells in cancer: the role revisited.
Curr Opin Immunol. 2017 Apr;45:43-51. doi: 10.1016/j.coi.2017.01.002. Epub 2017 Feb 10.
8
Myeloid-Derived Suppressor Cells.
Cancer Immunol Res. 2017 Jan;5(1):3-8. doi: 10.1158/2326-6066.CIR-16-0297.
9
The Heterogeneity of Ly6C Monocytes Controls Their Differentiation into iNOS Macrophages or Monocyte-Derived Dendritic Cells.
Immunity. 2016 Dec 20;45(6):1205-1218. doi: 10.1016/j.immuni.2016.12.001.
10
Novel insights in the regulation and function of macrophages in the tumor microenvironment.
Curr Opin Oncol. 2017 Jan;29(1):55-61. doi: 10.1097/CCO.0000000000000344.
Zotero 插件